LFA
SRPT icon

LGT Financial Advisors’s Sarepta Therapeutics SRPT Stock Holding History

LGT Financial Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-135
Closed -$16.4K – 670
2024
Q4 		$16.4K Buy
135
+43
+47% +$5.27K 0.04% 346
2024
Q3 		$11.5K Sell
92
-1
-1% -$138 0.03% 396
2024
Q2 		$14.7K Buy
+93
New +$11.9K 0.03% 384

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

LGT Financial Advisors's SRPT Position: Q1 2025 in Review

LGT Financial Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 135 shares — an estimated $16.4K sold.

LGT Financial Advisors first reported a position in SRPT in Q2 2024 and held it in 3 quarters. The position peaked at $16.4K in Q4 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • LGT Financial Advisors reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
  • LGT Financial Advisors sold 135 Sarepta Therapeutics shares in Q1 2025, an estimated $16.4K.
  • LGT Financial Advisors first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 3 quarters.
  • LGT Financial Advisors's Sarepta Therapeutics position peaked at $16.4K in Q4 2024.
  • 430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on LGT Financial Advisors's 13F filing for Q1 2025, filed 8 May 2025.